Skip to content

Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition

Pablo Mallaroni, Riccardo Paci, Sabrina Ritscher, Natasha L. Mason, Johannes T. Reckweg, Stefan W. Toennes, Eef L. Theunissen, Kim P. C. Kuypers, Johannes G. Ramaekers

Clinical Pharmacology & Therapeutics May 30, 2023 DOI: 10.1002/cpt.2958 via OpenAlex

Summary

AI-generated from the abstract

2,5‐dimethoxy‐4‐bromophenethylamine (2C‐B), a hallucinogen derived from mescaline, produces psychedelic effects of moderate depth, shorter in duration than psilocybin. In a double‐blind, placebo‐controlled study of 22 healthy participants with prior psychedelic experience, 20 mg of 2C‐B elicited alterations of waking consciousness, though psilocybin (15 mg) caused greater dysphoria, subjective impairment, auditory alterations, and ego dissolution. Both compounds equally slowed psychomotor performance and impaired spatial memory compared with placebo, and neither produced empathogenic effects on the Multifaceted Empathy Test. 2C‐B raised blood pressure transiently, similar to psilocybin, and its effects largely resolved within six hours.

Study at a glance

Characteristics Within-subjects, double-blind, placebo-controlled study Peer reviewed
Sample size 22
Population Healthy psychedelic-experienced participants
Interventions psilocybin placebo
Dose 20 mg 2C-B, 15 mg psilocybin
Topics Mescaline Psilocybin Serotonin
Keywords Hallucinogen Placebo Cognition
Citations 34
Key finding 2C‐B acts as a psychedelic of moderate experiential depth, with shorter duration and less dysphoria and ego dissolution than psilocybin, but similar psychomotor and memory impairments and pressor effects.

Abstract

2,5‐dimethoxy‐4‐bromophenethylamine (2C‐B) is a hallucinogenic phenethylamine derived from mescaline. Observational and preclinical data have suggested it to be capable of producing both subjective and emotional effects on par with other classical psychedelics and entactogens. Whereas it is the most prevalently used novel serotonergic hallucinogen to date, it's acute effects and distinctions from classical progenitors have yet to be characterized in a controlled study. We assessed for the first time the immediate acute subjective, cognitive, and cardiovascular effects of 2C‐B (20 mg) in comparison to psilocybin (15 mg) and placebo in a within‐subjects, double‐blind, placebo‐controlled study of 22 healthy psychedelic‐experienced participants. 2C‐B elicited alterations of waking consciousness of a psychedelic nature, with dysphoria, subjective impairment, auditory alterations, and affective elements of ego dissolution largest under psilocybin. Participants demonstrated equivalent psychomotor slowing and spatial memory impairments under either compound compared with placebo, as indexed by the Digit Symbol Substitution Test, Tower of London, and Spatial Memory Task. Neither compound produced empathogenic effects on the Multifaceted Empathy Test. 2C‐B induced transient pressor effects to a similar degree as psilocybin. The duration of self‐reported effects of 2C‐B was shorter than that of psilocybin, largely resolving within 6 hours. Present findings support the categorization of 2C‐B as a psychedelic of moderate experiential depth at doses given. Tailored dose‐effect studies are needed to discern the pharmacokinetic dependency of 2C‐B's experiential overlaps.

Explore topics

Comments

No comments yet.

Log in to comment